|
|
||||||||
in the Generation and Expansion of CD4+CD25+ Regulatory T Cells from Human Peripheral Blood1
Division of Rheumatology and Immunology, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033
| Abstract |
|---|
|
|
|---|
can induce certain
CD4+ T cells in the naive
(CD45RA+RO-) fraction in human peripheral
blood to develop powerful, contact-dependent suppressive activity that
is not antagonized by anti-TGF-
or anti-IL-10 mAbs. The
costimulatory effects of TGF-
on naive CD4+ T cells
up-regulated CD25 and CTLA-4 expression, increased their transition to
the activated phenotype, but decreased activation-induced apoptosis.
Suppressive activity was concentrated in the CD25+
fraction. These CD4+CD25+ regulatory cells
prevented CD8+ T cells from proliferating in response to
alloantigens and from becoming cytotoxic effector cells. Moreover,
these regulatory cells exerted their suppressive activities in
remarkably low numbers and maintained these effects even after they are
expanded. Once activated, their suppressive properties were Ag
nonspecific. Although <1% of naive CD4+ T cells expressed
CD25, depletion of this subset before priming with TGF-
markedly
decreased the generation of suppressive activity. This finding suggests
that CD4+CD25+ regulatory T cells induced ex
vivo are the progeny of thymus-derived regulatory T cells bearing a
similar phenotype. The adoptive transfer of these regulatory T cells
generated and expanded ex vivo has the potential to prevent rejection
of allogeneic organ grafts. | Introduction |
|---|
|
|
|---|
-chains (3, 4). These
CD4+CD25+ T cells
differentiate in the thymus and are exported to the periphery, where
they suppress the activation of potentially self-reactive cells
(3, 4, 5, 6, 7, 8). Injection of peripheral T cells from normal mice
depleted of CD4+CD25+ T
cells into athymic mice results in a high incidence of organ-specific
autoimmune disease (3, 4). Moreover, certain strains of
neonatally thymectomized mice develop multiorgan-specific autoimmunity
(9, 10). These mice lack
CD4+CD25+ cells because
they are not produced until 1 wk after birth (11, 12). CD4+CD25+ T cells are potent inhibitors of polyclonal T cell activation (12). After activation via the TCR, they inhibit IL-2 production by the responding T cells (13, 14, 15). Unlike other regulatory T cells, which produce inhibitory cytokines (16, 17), these cells suppress immune responses by a contact-dependent mechanism, at least in vitro (15). Others have described CD4+CD25+ cells that regulate anergy in neonatally tolerized mice (18).
Whether regulatory
CD4+CD25+ T cells exist in
humans and can be expanded in the periphery is not known. In addition
to the well-described suppressive effects of TGF-
on T cell function
(19, 20, 21, 22, 23, 24), this cytokine can also have positive effects,
which are predominantly on naive T cells (25). TGF-
can
synergize with IL-2 to prevent apoptosis and promote effector cell
function (26, 27, 28), and it has a crucial role in the
generation of CD8+ T cells that suppress Ab
production (29, 30). Here we report that TGF-
also
induces certain naive CD4+ T cells to become
cells that suppress the generation of T cell cytotoxic activity. Using
the allogeneic mixed lymphocyte reaction to stimulate naive
CD4+ cells that express 1% IL-2R
-chains, we
have learned that TGF-
enhances the number of
CD25+ cells and that some of these T cells
inhibit CD8+ cells from proliferating and
developing cytolytic activity on restimulation. Surprisingly, depletion
of the rare CD25+ cells in the
CD4+CD45RA+RO-
fraction markedly reduced the generation of suppressive activity; a
result suggesting that TGF-
stimulates and expands the small number
of thymus-derived
CD4+CD25+-regulatory T
cells that circulate in peripheral blood.
| Materials and Methods |
|---|
|
|
|---|
Antibodies used were anti-CD3 (UCHT1; PharMingen, San Diego,
CA); anti-CD4 (OKT4; American Type Culture Collection (ATCC),
Rockville, MD); anti-CD8 (OKT8; ATCC); anti-CD11b (OKM1; ATCC);
anti-CD16 (3G8); anti-CD25 (PharMingen); anti-CD45RA
(PharMingen); anti-CD45RO (UCHL-1; ATCC); anti-CD69
(PharMingen); anti-CD74 (anti-HLA-DR) (L243, ATCC);
anti-CD95 (Fas/APO-1) (PharMingen); anti-CD152 (CTLA-4;
PharMingen). FITC-conjugated annexin V and anti-IL-10 were also
purchased form PharMingen. Human rIL-2 was purchased from Chiron
(Emeryville, CA). Human rTGF-
1, anti-TGF-
, and IL-10 were
purchased from R&D Systems (Minneapolis, MN).
Cell isolation
PBMC were prepared from heparinized venous blood of healthy
adult volunteers by Ficoll-Hypaque (Pharmacia, Piscataway, NJ) density
gradient centrifugation as previously described (31). The
PBL were immediately rosetted with 2-aminoethylisothiouronium
bromide-treated SRBC. T cells were prepared from rosetting cells by
negative selection following depletion of CD16+
and CD74+ cells using immunomagnetic beads
(Dynal, Great Neck, NY). The percentage of CD3+
cells in this fraction was usually >95%. To obtain naive
CD45RA+RO-CD4+
T cells, SRBC-rosetting cells were stained with mAbs to CD8, CD16,
CD11b, CD74, and CD45RO and separated by negative selection using
immunomagnetic beads. The same mAbs were used to obtain naive
CD45RA+RO-CD8+
T cells except that CD4 was substituted for CD8. The purity of those T
cells was usually>95%. In some experiments,
CD25+ cells were also depleted by adding
anti-CD25 to the panel of mAbs. In other experiments, after naive
CD4+ cells had been cultured with irradiated
allogeneic stimulators ± TGF-
1 (1 ng/ml) for 5 days, the
CD4+CD25+ and
CD4+CD25- subsets were
obtained by sorting on a FACStarPlus flow
cytometer (Becton Dickinson, San Jose, CA) using FITC-conjugated
anti-CD25 and PE-conjugated anti-CD4. The resultant purity was
>98%. The nonrosetted cells from each donor were frozen and thawed
for use as stimulator cells in a subsequent experiment.
Cell cultures
Purified naive CD4+ T cells
(106 cells/ml) were added to 24-well microtiter
plates (Falcon, Lincoln Park, NJ) in 2-ml volumes. Cells were suspended
in AIM-V serum-free lymphocyte medium (Life Technologies, Gaithersburg,
MD) because serum contains significant amounts of latent TGF-
. Cells
were stimulated with irradiated (3000 cGy) allogeneic T cell-depleted
PBMC (106 cells/ml) in the presence or absence of
TGF-
(0.11 ng/ml) for 5 days. The phenotype of these alloactivated
CD4+ cells compared with unstimulated
CD4+ cells was assessed by flow cytometry. After
washing to remove residual cytokines, the regulatory effects of these
CD4+ subsets on syngeneic effector T cells was
assessed in secondary cultures. These cultures consisted of freshly
isolated effector T cells stimulated for 5 days with irradiated
allogeneic T cell-depleted PBMC in the presence or absence of the
indicated numbers of primed CD4+ T cells. In some
experiments, various numbers of sorted (see above)
CD4+CD25+ or
CD4+CD25- were added to
the secondary cultures. We assessed effector T cell phenotype,
proliferative activity, and generation of CTL activity. In some
secondary cultures, the medium contained 10% AB human serum (Omega
Scientific, Tarzana, CA) instead of FCS.
Similar to the studies of Thornton and Shevach (13), we used the Transwell chambers (Corning Costar, Cambridge, MA) to assess whether surface contact was necessary for suppressive effects in the secondary cultures. These experiments were conducted in 24-well plates (0.8 ml) with effector T cells and irradiated (3000 cGy) allogeneic T cell-depleted PBMC in the presence or absence of conditioned CD4+ T cells mixed with irradiated stimulator cells in the Transwell. In other experiments, sorted CD4+CD25+ T cells were cultured with IL-2, 10 U/ml, for 57 days to determine their capacity for expansion. Various numbers of these cells were added to fresh T cells and irradiated stimulator cells, and their effect on the generation of CTL activity was assessed as described above.
Cytotoxicity assays
The cytotoxic activity was measured by a standard 4 h chromium release assay. In brief, 5 x 103 51Cr-labeled target cells (stimulator Con A blasts) were incubated with graded numbers of effector T cells in 200 µl medium in 96-well round-bottom microtiter plates (Falcon). The plates were centrifuged and incubated for 4 h at 37°C. Then supernatants were harvested and counted in a gamma counter. All test samples were measured in triplicate. The percentage of specific 51Cr release was calculated as: percent lysis = [(cpm released experimental - cpm spontaneous)/(cpm total lysis - cpm spontaneous)] x 100.
Proliferation assays
Purified T cells (105 cells/well) were cultured in 200 µl flat-bottom 96-well plates (Falcon) with irradiated (3000 cGy) allogeneic T cell-depleted PBMC (105 cells/well) and the indicated numbers of conditioned CD4+ T cell for 3 or 5 days at 37°C and 5% CO2. Cultures were pulsed with [3H]TdR for the last 18 h of culture. All tests were conducted in triplicate.
Immunofluorescence analysis
Cell surface Ag expressions on both conditioned CD4+ T cells and effector T cells were determined by immunofluorescence. Cells (105) were labeled with FITC-conjugated (anti-CD4, anti-CD25, anti-CD45RO, anti-CD69), PE-conjugated (anti-CD8, anti-CD25, anti-CD45RA, anti-CD95) or CyChrome-conjugated (anti-CD4, anti-CD8) mAbs. Cells were incubated with the appropriate mAbs for 30 min at 4°C in PBS with 0.1% BSA and 0.02 mM NaN3. After washing, the labeled cell samples were analyzed on a FACStarPlus flow cytometer using Cellquest software (Becton Dickinson).
To analyze cell divisions of effector T cells, effector T cells were labeled with CFSE (Molecular Probes, Eugene, OR). In brief, cells were washed and resuspended at a concentration of 107/ml in PBS. CFSE was added at a final concentration of 0.5 µM and incubated for 10 min at 37°C. The reaction was stopped by washing the cells with RPMI 1640 containing 10% FCS. After the culture of labeled effector T cells (106 cells/ml) with irradiated (3000 cGy) allogeneic T cell-depleted PBMC (106 cells/ml) in the presence or absence of the indicated numbers of conditioned CD4+ T cells, CFSE levels were analyzed by flow cytometry.
To learn whether CD4+ T cells primed with TGF-
could proliferate in response to the stimulator cells, these T cells
and those primed without TGF-
were rested for 3 days, labeled with
CFSE, and restimulated with irradiated E rosette-negative cells in
medium containing 10% type AB human serum. Intensity of CFSE was
determined after 37 days of culture.
Statistical analysis
The significance of the results was analyzed by Students t test performed using GraphPad software (GraphPad, San Diego, CA).
| Results |
|---|
|
|
|---|
can induce alloactivated naive CD4+ T cells to
develop suppressive activity
Naive CD4+ cells developed potent
suppressive activity when activated in the presence of TGF-
. These
CD4+ T cells had the capacity to block the
generation of CTL activity against allogeneic target cells. In a
two-step coculture experiment,
CD4+CD45RA+
RO- T cells were first incubated with irradiated
allogeneic stimulator cells ± TGF-
1 for 5 days. Various
numbers of these cells were then added to fresh T cells and stimulator
cells, and the effect of these cells on the generation of CTL activity
was assessed. On assay with chromium-labeled allogeneic target cells,
CD4+ cells that had been primed in the presence
of TGF-
almost completely blocked responder T cells from killing,
whereas control CD4+ cells generally had minimal
to modest suppressive activity (Fig. 1
A). Activation of
CD4+ cells was needed for the development of
inhibitory activity. CD4+ suppressor cells that
had been primed with alloantigens in the presence of TGF-
will be
called CD4reg. Unlike TGF-
, priming of the
CD4+ cells with IL-10 did not induce suppressive
activity (Fig. 1
B). TGF-
could also costimulate purified
CD4+CD45RA-CD45RO+
cells to inhibit allo-CTL activity (Fig. 1
C). However, the
effects of these cells on the development of T cell cytotoxicity were
more variable. In some experiments, the effects of CD4 cells primed
without TGF-
(CD4con) were also strongly suppressive, and the
presence of TGF-
did not further increase this effect. Finally,
naive CD8+ T cells primed with stimulator cells
also developed moderate suppressive activity, but under these
experimental conditions the presence of TGF-
with few exceptions,
did not enhance this activity (Fig. 1
D),
|
-induced human CD4+ cells alloactivated in
the presence of TGF-
appeared to require surface contact (Fig. 2
and
IL-10. These Abs, however, did not diminish the suppressive effects of
CD4reg (Fig. 2
, however, completely abolished
suppressive activity (result not shown).
|
on alloactivated CD4+
T cells
Activation of naive CD4+ T cells in the
presence of TGF-
enabled them to respond more vigorously to
alloantigens, accelerated their conversion to the activated phenotype,
and increased their viability. Fig. 3
indicates properties of control and TGF-
-conditioned
CD4+ cells after 5 days of culture.
Allostimulated CD4+ cells displayed the typical
features of activation and some were already undergoing
activation-induced cell death as indicated by annexin V staining.
Importantly, those alloactivated in the presence of TGF-
were even
larger, some stained more intensely with CD4, and expression of CD25
was markedly increased. Table I
shows the
significant increase in mean values for expression of CD25 and for both
intracellular and surface expression of CTLA-4 in 13 separate
experiments. A greater percentage of CD4reg had also down-regulated
surface expression of CD45RA (Fig. 3
). Significantly, annexin V
staining was markedly decreased, and the total number of CD4reg
recovered was 5060% greater than control CD4+
cells. Thus, although CD4reg were more intensively activated that
control CD4 cells, they were also more resistant to activation-induced
apoptosis.
|
|
Similar to the murine CD4+-regulatory T
cells described by others (11, 12, 13, 14, 15), separation of CD4reg
into CD25+ and CD25-
fractions by cell sorting revealed that almost all of the suppressive
activity was contained in the CD25+ fraction
(Fig. 4
A). The
CD4+CD25- fraction
displayed only minimal suppressive activity. Moreover, the
CD4+CD25+ cells were very
potent as indicated by their ability to markedly inhibit the generation
of CTL activity in very low numbers. Fig. 4
B shows that
suppressive activity was only slightly diminished when the numbers of
the CD4+ suppressor cells were reduced from 25%
to 3% of total T cells. With this small number of added
CD4+ cells, the minimal suppressive activity
mediated by the CD25- subset had
disappeared.
|
Unlike CD4+-regulatory T cells generated by
repeated stimulation with IL-10, which have low proliferative capacity
(32), CD4reg induced in the presence of TGF-
proliferated in response to alloantigens and IL-2 and retained their
suppressive capacity. Fig. 5
shows the
response of CD4reg and CD4con when cultured with stimulator cells.
After priming, the cells were washed to remove residual TGF-
and
cultured for 3 days; CFSE labeling revealed that they had returned to
the resting state. After the addition of allogeneic stimulator cells to
CD4+ cells freshly labeled with CFSE, a stronger
proliferative response by CD4reg was apparent at day 3 and clearly
evident by day 5.
|
|
CD4reg blocked the proliferative response of responder T cells to
alloantigens (Fig. 7
A). Gating
on CD8+ cells by flow cytometry after a 5-day
culture, these alloactivated T cells displayed the expected marked
increase in CD25, increased expression of CD69 and Fas (CD95), and
evidence of cell division by CFSE-labeled and propidium iodide-labeled
effector T cells. Moreover, some CD8+ cells were
undergoing activation-induced cell death as indicated by annexin V
staining. In sharp contrast, in cultures containing CD4reg,
up-regulation of CD25, CD69, and Fas by CD8+
cells was markedly inhibited, and almost none underwent apoptosis or
cell division. Studies of the absolute numbers of
CD8+ cells in culture revealed only a minimal
change from the total count. Thus, CD4reg prevented
CD8+ T cells from responding to alloantigens.
|
did not affect
the generation of CTL activity by fresh T cells against donor B, as
shown above. However, the addition of these control
CD4+ cells to T cells responding to third party,
donor C stimulator cells increased the CTL activity generated. By
contrast, CD4reg specific for donor B also suppressed the development
of CTL activity against donor C.
|
|
had costimulated CD25- T cells to
develop suppressive activity. However, we could not exclude the
possibility that these CD4reg were derived from the
CD25+ subset. To test this possibility, naive
CD4+ cells were depleted of
CD25+ cells and then primed in the presence of
TGF-
. We found that, as before, TGF-
enhanced the expression of
CD25 and the percentage of CD25+ cells. Moreover,
the percentage of CD25+ cells after
alloactivation was only modestly less in the subset that had initially
been depleted of cells bearing this marker. However, after depletion of
CD25+ naive CD4+ cells, the
suppressive activity induced by TGF-
was markedly reduced (Fig. 10
are the progeny of thymus-derived
CD4+CD25+ T cells.
|
| Discussion |
|---|
|
|
|---|
on naive CD4+
CD45RA+ T cells circulating in the periphery can
result in the development of remarkably potent suppressive activity.
TGF-
enhanced expression of CD25 and CTLA-4 and accelerated their
differentiation to the CD45RA--activated
phenotype. The phenotype and suppressive effects of these
CD4+ cells were similar, if not identical, with
the thymus-derived
CD4+CD25+-regulatory T
cells described by others (3, 4, 5, 6, 7, 8, 33). Moreover, we have
shown that CD4reg block CD8+ T cells from
responding to alloantigens and that this effect is only partially
reversed by exogenous IL-2. As expected, suppressive activity was also
found in the CD45RA-RO+
fraction of CD4+cells, and TGF-
could also
enhance this activity, but this effect was more variable.
Previously we had reported that TGF-
has a crucial role in the
generation of CD8+ T cells that suppress Ab
production (29, 30). In those studies,
CD8+ cells were activated with Con A in the
presence of TGF-
for 24 h, whereas in the present study
alloantigen-activated CD4+ cells required a
longer exposure with this cytokine for optimal up-regulation of CD25
and induction of potent suppressive activity. The more vigorous
response of alloactivated naive CD4+ cells in the
presence of TGF-
and the increased viability of these activated
cells are consistent with the previously described positive effects of
this cytokine on naive T cells (25, 26). We suggest that
the costimulatory effects of TGF-
on naive T cells induce them to
develop down-regulatory activity instead of becoming conventional T
effector cells.
A surprising finding of this study was the principal source of CD4reg.
Depletion studies revealed that these cells were derived from the rare
CD25+ cells present in the
CD45RA+RO- fraction of
peripheral blood. As previously reported by others, TGF-
can
up-regulate CD25 expression by activated naive T cells
(25). However, those that were
CD25- before activation generally had minimal
suppressive activity at the time they were examined. It is not
unlikely, however, that naive
CD4+CD25- cells can also
develop down-regulatory activity. We have recently observed that naive
CD4+ T cells primed with superantigen in the
presence of TGF-
produce inhibitory amounts of active TGF-
when
restimulated one or more times (34).
Consistent with studies of murine
CD4+CD25+ regulatory T
cells, human CD4reg induced by TGF-
inhibit T cell responses by
blocking responsiveness rather than by killing them. Although we
considered the possibility that the failure of
CD8+ cells to develop CTL activity could be due
to cytolytic effects of CD4reg against the allogeneic stimulator cells,
this was unlikely for the following reasons: 1) the numbers of CD4reg
required for significant inhibition were too small for a significant
effect on the Ag-presenting cells; 2) CD4reg had weak CTL activity,
even after expansion in IL-2; and 3) other investigators have reported
that TGF-
inhibits the development of CTL activity (21, 22).
Murine CD4+CD25+ cells inhibit IL-2 production by Ag-stimulated T cells and thereby block T cell proliferation (14, 15), a result in agreement with the present study. Another group has reported that CD4+CD25+ cells render CD8+ cells anergic. These workers injected semiallogeneic splenocytes into neonatal mice and observed long term Ag-specific CD8 cell nonresponsiveness. Interestingly, although IL-2 could not restore CD8 CTL activity, this result was achieved after removal of regulatory CD4+CD25+ T cells from the cell suspensions (18). Thus, as long as regulatory T cells were present, even IL-2 could not reverse anergy. In in vitro studies, the anergy induced by mouse CD4+CD25+ cells can be overcome by IL-2 or anti-CD28 (14, 15). In the present experiments, the addition of exogenous IL-2 to cultures containing human CD4reg restored CD8 CTL activity partially but not completely. This result is consistent with the role of CD4+CD25+ cells in sustaining transplantation tolerance (18).
The suppressive effects of human CD4reg, like mouse CD4+CD25+ T cells, are Ag nonspecific. Once activated, these regulatory T cells have broad suppressive effects (14, 15). In the present experiments, besides inhibiting T cells responding to the same stimulator cells used to induce them, human CD4reg equally inhibited T cells responding to third party stimulator cells.
CTLA-4 is a potent inhibitor of T cell responses (35, 36).
Two groups have recently reported that CTLA-4 plays a key role in the T
cell-mediated dominant immunological self tolerance. Blockade of CTLA-4
abolished the suppressive activities of
CD4+CD25+ T cells
(37, 38). In this study, the costimulatory effects of
TGF-
markedly up-regulated CTLA-4. In preliminary studies, Fab
anti-CTLA-4 Abs obtained from Dr. B. M. Carreno (Genetics
Institute, Cambridge, MA) did not inhibit the suppressive effects of
CD4reg.
The mechanism of action of CD4reg remains to be determined but is
clearly different from Tr1 CD4+ cells repeatedly
stimulated with IL-10 or activated with immature dendritic cells
(32, 39). Tr1 cells are anergic, and their
immunosuppressive effects are mediated by IL-10 and TGF-
. Anergic T
cells suppress other T cell responses by targeting APC (40, 41). Under the experimental conditions described here, IL-10
could not be substituted for TGF-
to induce CD4reg (Fig. 1
B). Moreover, CD4reg had the characteristics of activated
rather than anergic cells in primary cultures (Fig. 3
), and on
restimulation with alloantigen these T cells proliferated even more
vigorously than control CD4+ cells (Fig. 5
). In
agreement with the studies of Thornton and Shevach (15),
the suppressive activities were abolished by separation of the
regulatory cells and effector cells by a semipermeable membrane,
whereas neutralizing anti-TGF-
and anti-IL-10 Abs did not
have this effect (Fig. 2
C).
To explain how the addition of <1 regulatory T cell to 100 T cells can
have potent inhibitory effects, it is likely that these cells expand
rapidly. Consistent with this possibility, the suppressive effects of
CD4reg were radiosensitive even after they were generated (Fig. 6
). The
effects of irradiation on suppressor T cells are well known
(42, 43, 44, 45). It is also possible that CD4reg are part of a
network that facilitates other cells to produce inhibitory cytokines
(46). This would explain why CD4reg have contact-dependent
inhibitory effects in vitro but appear to depend on the production of
TGF-
and IL-10 in vivo (2, 47, 48).
The ability to generate powerful regulatory T cells ex vivo has
immediate clinical relevance. Allogeneic stem cell transplantation has
great potential for the treatment of certain individuals with
neoplastic or heritable diseases, but is limited by graft vs host
disease. Similarly, although there has been great progress in managing
acute rejection after transplantation of solid organs, survival of
kidney grafts after 1 year has not increased significantly
(49). The use of regulatory T cells generated ex vivo for
the prevention of graft rejection as well as a treatment for
autoimmunity has great potential. Unlike Tr1-like cells, both murine
CD4+CD25+ T cells
(15) and the comparable human T cell subset described in
this report can be propagated ex vivo and retain their powerful
suppressive effects after expansion. The positive effects of TGF-
on
the viability of these regulatory cells are also encouraging. These
findings add to the potential of adoptive regulatory T cell
immunotherapy as a novel treatment strategy that will lack the toxic
side effects of the agents currently in use.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Current address: Niigata University, School of Medicine, Third Department of Internal Medicine, 1-757 Asahimachi-dori, Niigata, Niigata 951-8510, Japan. ![]()
3 Address correspondence and reprint requests to Dr. David A. Horwitz, Division of Rheumatology and Immunology, University of Southern California, Keck School of Medicine, 2011 Zonal Avenue, HMR 711, Los Angeles, CA 90033. E-mail address: dhorwitz{at}hsc.usc.edu ![]()
Received for publication November 15, 2000. Accepted for publication April 16, 2001.
| References |
|---|
|
|
|---|
-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151.[Abstract]
-chain (CD25) and having a functionally transitional nature into memory cells. Int. Immunnol. 3:1349.
but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RBlow CD4+ T cells. J. Exp. Med. 183:2669.
. Annu. Rev. Immunol. 16:137.[Medline]
can inhibit human T lymphocyte proliferation through paracrine and autocrine mechanisms. Cell. Immunol. 150:45.[Medline]
and reversal by tumor necrosis factor
. J. Exp. Med. 166:991.
. J. Immunol. 146:3289.[Abstract]
and transforming growth factor-
. Cell. Immunol. 126:47.[Medline]
-producing cells from naive CD4+ T cells: IL-4 and IFN-
have opposing effects, while TGF-
positively regulates its own production. J. Immunol. 160:5719.
l on the activation of human naive and memory CD4+ T
lymphocytes. Int. Immunol. 6:63.l.
1 and interleukin 2 synergize to prevent apoptosis and promote effector function. J. Exp. Med. 182:699.
1. J. Immunol. 156:459.[Abstract]
is a potent inducer of human effector T cells. J. Immunol. 153:4367.[Abstract]
in the generation of suppression: an interaction between CD8+ T cells and NK cells. J. Exp. Med. 180:1937.
: contrasting effects of anti-CD2 and anti-CD3. J. Immunol. 160:2248.
results in
the production of the active form of this cytokine. FASEB
14:A989.
This article has been cited by other articles:
![]() |
G. Du, L. Jin, X. Han, Z. Song, H. Zhang, and W. Liang Naringenin: A Potential Immunomodulator for Inhibiting Lung Fibrosis and Metastasis Cancer Res., April 1, 2009; 69(7): 3205 - 3212. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ahmadzadeh, A. Felipe-Silva, B. Heemskerk, D. J. Powell Jr, J. R. Wunderlich, M. J. Merino, and S. A. Rosenberg FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions Blood, December 15, 2008; 112(13): 4953 - 4960. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Imarai, E. Candia, C. Rodriguez-Tirado, J. Tognarelli, M. Pardo, T. Perez, D. Valdes, S. Reyes-Cerpa, P. Nelson, C. Acuna-Castillo, et al. Regulatory T Cells Are Locally Induced during Intravaginal Infection of Mice with Neisseria gonorrhoeae Infect. Immun., December 1, 2008; 76(12): 5456 - 5465. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lampinen, M. Backman, O. Winqvist, F. Rorsman, A. Ronnblom, P. Sangfelt, and M. Carlson Different regulation of eosinophil activity in Crohn's disease compared with ulcerative colitis J. Leukoc. Biol., December 1, 2008; 84(6): 1392 - 1399. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Chen, X. Liang, A. J. Peterson, D. H. Munn, and B. R. Blazar The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation J. Immunol., October 15, 2008; 181(8): 5396 - 5404. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Filippi, A. E. Juedes, J. E. Oldham, E. Ling, L. Togher, Y. Peng, R. A. Flavell, and M. G. von Herrath Transforming Growth Factor-{beta} Suppresses the Activation of CD8+ T-Cells When Naive but Promotes Their Survival and Function Once Antigen Experienced: A Two-Faced Impact on Autoimmunity Diabetes, October 1, 2008; 57(10): 2684 - 2692. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Zhao, S. Yu, D. C. Fitzgerald, M. Elbehi, B. Ciric, A. M. Rostami, and G.-X. Zhang IL-12R{beta}2 Promotes the Development of CD4+CD25+ Regulatory T Cells J. Immunol., September 15, 2008; 181(6): 3870 - 3876. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kaplan, L Woodworth, K Smith, J Coco, A Vitsky, and J. McPherson Therapeutic benefit of treatment with anti-thymocyte globulin and latent TGF-{beta}1 in the MRL/lpr lupus mouse model Lupus, September 1, 2008; 17(9): 822 - 831. [Abstract] [PDF] |
||||
![]() |
S. Radhakrishnan, R. Cabrera, E. L. Schenk, P. Nava-Parada, M. P. Bell, V. P. Van Keulen, R. J. Marler, S. J. Felts, and L. R. Pease Reprogrammed FoxP3+ T Regulatory Cells Become IL-17+ Antigen-Specific Autoimmune Effectors In Vitro and In Vivo J. Immunol., September 1, 2008; 181(5): 3137 - 3147. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sehrawat, S. Suvas, P. P. Sarangi, A. Suryawanshi, and B. T. Rouse In Vitro-Generated Antigen-Specific CD4+ CD25+ Foxp3+ Regulatory T Cells Control the Severity of Herpes Simplex Virus-Induced Ocular Immunoinflammatory Lesions J. Virol., July 15, 2008; 82(14): 6838 - 6851. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gil-Guerrero, J. Dotor, I. L. Huibregtse, N. Casares, A. B. Lopez-Vazquez, F. Rudilla, J. I. Riezu-Boj, J. Lopez-Sagaseta, J. Hermida, S. Van Deventer, et al. In Vitro and In Vivo Down-Regulation of Regulatory T Cell Activity with a Peptide Inhibitor of TGF-{beta}1 J. Immunol., July 1, 2008; 181(1): 126 - 135. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sehrawat and B. T. Rouse Anti-Inflammatory Effects of FTY720 against Viral-Induced Immunopathology: Role of Drug-Induced Conversion of T Cells to Become Foxp3+ Regulators J. Immunol., June 1, 2008; 180(11): 7636 - 7647. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. P. Sarangi, S. Sehrawat, S. Suvas, and B. T. Rouse IL-10 and Natural Regulatory T Cells: Two Independent Anti-Inflammatory Mechanisms in Herpes Simplex Virus-Induced Ocular Immunopathology J. Immunol., May 1, 2008; 180(9): 6297 - 6306. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Richer, N. Straka, D. Fang, I. Shanina, and M. S. Horwitz Regulatory T-Cells Protect From Type 1 Diabetes After Induction by Coxsackievirus Infection in the Context of Transforming Growth Factor-{beta} Diabetes, May 1, 2008; 57(5): 1302 - 1311. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Alisa, S. Boswell, A. A. Pathan, L. Ayaru, R. Williams, and S. Behboudi Human CD4+ T Cells Recognize an Epitope within {alpha}-Fetoprotein Sequence and Develop into TGF-{beta}-Producing CD4+ T Cells J. Immunol., April 1, 2008; 180(7): 5109 - 5117. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Sumpter, K. K. Payne, and D. S. Wilkes Regulation of the NFAT pathway discriminates CD4+CD25+ regulatory T cells from CD4+CD25- helper T cells J. Leukoc. Biol., March 1, 2008; 83(3): 708 - 717. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Cook, A. A. Bickerstaff, J.-J. Wang, T. Nadasdy, P. Della Pelle, R. B. Colvin, and C. G. Orosz Spontaneous Renal Allograft Acceptance Associated with "Regulatory" Dendritic Cells and IDO J. Immunol., March 1, 2008; 180(5): 3103 - 3112. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Aricha, T. Feferman, S. Fuchs, and M. C. Souroujon Ex Vivo Generated Regulatory T Cells Modulate Experimental Autoimmune Myasthenia Gravis J. Immunol., February 15, 2008; 180(4): 2132 - 2139. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Li, E. J. Gowans, C. Chougnet, M. Plebanski, and U. Dittmer Natural Regulatory T Cells and Persistent Viral Infection J. Virol., January 1, 2008; 82(1): 21 - 30. [Full Text] [PDF] |
||||
![]() |
R. K. Selvaraj and T. L. Geiger A Kinetic and Dynamic Analysis of Foxp3 Induced in T Cells by TGF-beta J. Immunol., June 15, 2007; 178(12): 7667 - 7677. [Abstract] [Full Text] [PDF] |
||||
![]() |
I L Huibregtse, A U van Lent, and S J H van Deventer Immunopathogenesis of IBD: insufficient suppressor function in the gut? Gut, April 1, 2007; 56(4): 584 - 592. [Full Text] [PDF] |
||||
![]() |
S. P. Hilchey, A. De, L. M. Rimsza, R. B. Bankert, and S. H. Bernstein Follicular Lymphoma Intratumoral CD4+CD25+GITR+ Regulatory T Cells Potently Suppress CD3/CD28-Costimulated Autologous and Allogeneic CD8+CD25- and CD4+CD25- T Cells J. Immunol., April 1, 2007; 178(7): 4051 - 4061. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. N. Couper, D. G. Blount, J. B. de Souza, I. Suffia, Y. Belkaid, and E. M. Riley Incomplete Depletion and Rapid Regeneration of Foxp3+ Regulatory T Cells Following Anti-CD25 Treatment in Malaria-Infected Mice J. Immunol., April 1, 2007; 178(7): 4136 - 4146. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Zheng, J. Wang, P. Wang, J. D. Gray, and D. A. Horwitz IL-2 Is Essential for TGF-beta to Convert Naive CD4+CD25- Cells to CD25+Foxp3+ Regulatory T Cells and for Expansion of These Cells J. Immunol., February 15, 2007; 178(4): 2018 - 2027. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Carrier, J. Yuan, V. K. Kuchroo, and H. L. Weiner Th3 Cells in Peripheral Tolerance. II. TGF-beta-Transgenic Th3 Cells Rescue IL-2-Deficient Mice from Autoimmunity J. Immunol., January 1, 2007; 178(1): 172 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mitsuo, S. Morimoto, Y. Nakiri, J. Suzuki, H. Kaneko, Y. Tokano, H. Tsuda, Y. Takasaki, and H. Hashimoto Decreased CD161+CD8+ T cells in the peripheral blood of patients suffering from rheumatic diseases Rheumatology, December 1, 2006; 45(12): 1477 - 1484. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Y. Lan, Z. Wang, G. Raimondi, W. Wu, B. L. Colvin, A. De Creus, and A. W. Thomson "Alternatively Activated" Dendritic Cells Preferentially Secrete IL-10, Expand Foxp3+CD4+ T Cells, and Induce Long-Term Organ Allograft Survival in Combination with CTLA4-Ig J. Immunol., November 1, 2006; 177(9): 5868 - 5877. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Lawson, A. K. Brown, V. Bejarano, S. H. Douglas, C. H. Burgoyne, A. S. Greenstein, A. W. Boylston, P. Emery, F. Ponchel, and J. D. Isaacs Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood Rheumatology, October 1, 2006; 45(10): 1210 - 1217. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mahic, S. Yaqub, C. C. Johansson, K. Tasken, and E. M. Aandahl FOXP3+CD4+CD25+ Adaptive Regulatory T Cells Express Cyclooxygenase-2 and Suppress Effector T Cells by a Prostaglandin E2-Dependent Mechanism J. Immunol., July 1, 2006; 177(1): 246 - 254. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shimoda, F. Mmanywa, S. K. Joshi, T. Li, K. Miyake, J. Pihkala, J. A. Abbas, and P. A. Koni Conditional Ablation of MHC-II Suggests an Indirect Role for MHC-II in Regulatory CD4 T Cell Maintenance. J. Immunol., June 1, 2006; 176(11): 6503 - 6511. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-L. Cheng, H.-W. Chen, J.-P. Tsai, Y.-P. Lee, Y.-C. Shih, C.-M. Chang, and C.-C. Ting Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta} J. Leukoc. Biol., May 1, 2006; 79(5): 1033 - 1042. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Guyot-Revol, J. A. Innes, S. Hackforth, T. Hinks, and A. Lalvani Regulatory T Cells Are Expanded in Blood and Disease Sites in Patients with Tuberculosis Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 803 - 810. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Fecci, D. A. Mitchell, J. F. Whitesides, W. Xie, A. H. Friedman, G. E. Archer, J. E. Herndon II, D. D. Bigner, G. Dranoff, and J. H. Sampson Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res., March 15, 2006; 66(6): 3294 - 3302. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Zheng, J. H. Wang, W. Stohl, K. S. Kim, J. D. Gray, and D. A. Horwitz TGF-beta Requires CTLA-4 Early after T Cell Activation to Induce FoxP3 and Generate Adaptive CD4+CD25+ Regulatory Cells J. Immunol., March 15, 2006; 176(6): 3321 - 3329. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vojdani and J. Erde Regulatory T Cells, a Potent Immunoregulatory Target for CAM Researchers: The Ultimate Antagonist (I). Evid. Based Complement. Altern. Med., March 1, 2006; 3(1): 25 - 30. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Zheng, L. Meng, J. H. Wang, M. Watanabe, M. L. Barr, D. V. Cramer, J. D. Gray, and D. A. Horwitz Transfer of regulatory T cells generated ex vivo modifies graft rejection through induction of tolerogenic CD4+CD25+ cells in the recipient Int. Immunol., February 1, 2006; 18(2): 279 - 289. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mesel-Lemoine, M. Cherai, S. Le Gouvello, M. Guillot, V. Leclercq, D. Klatzmann, V. Thomas-Vaslin, and F. M. Lemoine Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy Blood, January 1, 2006; 107(1): 381 - 388. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Skapenko, J. R. Kalden, P. E. Lipsky, and H. Schulze-Koops The IL-4 Receptor {alpha}-Chain-Binding Cytokines, IL-4 and IL-13, Induce Forkhead Box P3-Expressing CD25+CD4+ Regulatory T Cells from CD25-CD4+ Precursors J. Immunol., November 1, 2005; 175(9): 6107 - 6116. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-P. Kim, B.-G. Kim, J. Letterio, and W. J. Leonard Smad-dependent Cooperative Regulation of Interleukin 2 Receptor {alpha} Chain Gene Expression by T Cell Receptor and Transforming Growth Factor-{beta} J. Biol. Chem., October 7, 2005; 280(40): 34042 - 34047. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. P Cobbold T cell tolerance induced by therapeutic antibodies Phil Trans R Soc B, September 29, 2005; 360(1461): 1695 - 1705. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Carter, G. M. Calabrese, M. Naganuma, and U. Lorenz Deficiency of the Src Homology Region 2 Domain-Containing Phosphatase 1 (SHP-1) Causes Enrichment of CD4+CD25+ Regulatory T Cells J. Immunol., June 1, 2005; 174(11): 6627 - 6638. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Brusko, C. H. Wasserfall, A. Agarwal, M. H. Kapturczak, and M. A. Atkinson An Integral Role for Heme Oxygenase-1 and Carbon Monoxide in Maintaining Peripheral Tolerance by CD4+CD25+ Regulatory T Cells J. Immunol., May 1, 2005; 174(9): 5181 - 5186. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Fahlen, S. Read, L. Gorelik, S. D. Hurst, R. L. Coffman, R. A. Flavell, and F. Powrie T cells that cannot respond to TGF-{beta} escape control by CD4+CD25+ regulatory T cells J. Exp. Med., March 7, 2005; 201(5): 737 - 746. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Rao, A. L. Petrone, and P. D. Ponath Differentiation and Expansion of T Cells with Regulatory Function from Human Peripheral Lymphocytes by Stimulation in the Presence of TGF-{beta} J. Immunol., February 1, 2005; 174(3): 1446 - 1455. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Gunnlaugsdottir, S. M. Maggadottir, and B. R. Ludviksson Anti-CD28-induced co-stimulation and TCR avidity regulates the differential effect of TGF-{beta}1 on CD4+ and CD8+ naive human T-cells Int. Immunol., January 1, 2005; 17(1): 35 - 44. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Curotto de Lafaille, A. C. Lino, N. Kutchukhidze, and J. J. Lafaille CD25- T Cells Generate CD25+Foxp3+ Regulatory T Cells by Peripheral Expansion J. Immunol., December 15, 2004; 173(12): 7259 - 7268. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Huber, C. Schramm, H. A. Lehr, A. Mann, S. Schmitt, C. Becker, M. Protschka, P. R. Galle, M. F. Neurath, and M. Blessing Cutting Edge: TGF-{beta} Signaling Is Required for the In Vivo Expansion and Immunosuppressive Capacity of Regulatory CD4+CD25+ T Cells J. Immunol., December 1, 2004; 173(11): 6526 - 6531. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jinushi, T. Takehara, T. Tatsumi, T. Kanto, T. Miyagi, T. Suzuki, Y. Kanazawa, N. Hiramatsu, and N. Hayashi Negative Regulation of NK Cell Activities by Inhibitory Receptor CD94/NKG2A Leads to Altered NK Cell-Induced Modulation of Dendritic Cell Functions in Chronic Hepatitis C Virus Infection J. Immunol., November 15, 2004; 173(10): 6072 - 6081. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Weiss, V. Donkova-Petrini, L. Caccavelli, M. Balbo, C. Carbonneil, and Y. Levy Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients Blood, November 15, 2004; 104(10): 3249 - 3256. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Moseman, X. Liang, A. J. Dawson, A. Panoskaltsis-Mortari, A. M. Krieg, Y.-J. Liu, B. R. Blazar, and W. Chen Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells J. Immunol., October 1, 2004; 173(7): 4433 - 4442. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. La Cava, F. M. Ebling, and B. H. Hahn Ig-Reactive CD4+CD25+ T Cells from Tolerized (New Zealand Black x New Zealand White)F1 Mice Suppress In Vitro Production of Antibodies to DNA J. Immunol., September 1, 2004; 173(5): 3542 - 3548. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schramm, S. Huber, M. Protschka, P. Czochra, J. Burg, E. Schmitt, A. W. Lohse, P. R. Galle, and M. Blessing TGF{beta} regulates the CD4+CD25+ T-cell pool and the expression of Foxp3 in vivo Int. Immunol., September 1, 2004; 16(9): 1241 - 1249. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Vasu, B. S. Prabhakar, and M. J. Holterman Targeted CTLA-4 Engagement Induces CD4+CD25+CTLA-4high T Regulatory Cells with Target (Allo)antigen Specificity J. Immunol., August 15, 2004; 173(4): 2866 - 2876. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-B. Park, D.-J. Paik, E. Jang, S. Hong, and J. Youn Acquisition of anergic and suppressive activities in transforming growth factor-{beta}-costimulated CD4+CD25- T cells Int. Immunol., August 1, 2004; 16(8): 1203 - 1213. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Viguier, F. Lemaitre, O. Verola, M.-S. Cho, G. Gorochov, L. Dubertret, H. Bachelez, P. Kourilsky, and L. Ferradini Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells J. Immunol., July 15, 2004; 173(2): 1444 - 1453. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mamura, W. Lee, T. J. Sullivan, A. Felici, A. L. Sowers, J. P. Allison, and J. J. Letterio CD28 disruption exacerbates inflammation in Tgf-{beta}1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-{beta}1 Blood, June 15, 2004; 103(12): 4594 - 4601. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Oz, M. Ray, T. S. Chen, and C. J. McClain Efficacy of a Transforming Growth Factor {beta}2 Containing Nutritional Support Formula in a Murine Model of Inflammatory Bowel Disease J. Am. Coll. Nutr., June 1, 2004; 23(3): 220 - 226. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Sumpter and D. S. Wilkes Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection Am J Physiol Lung Cell Mol Physiol, June 1, 2004; 286(6): L1129 - L1139. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Zheng, J. H. Wang, J. D. Gray, H. Soucier, and D. A. Horwitz Natural and Induced CD4+CD25+ Cells Educate CD4+CD25- Cells to Develop Suppressive Activity: The Role of IL-2, TGF-{beta}, and IL-10 J. Immunol., May 1, 2004; 172(9): 5213 - 5221. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Peng, Y. Laouar, M. O. Li, E. A. Green, and R. A. Flavell TGF-{beta} regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes PNAS, March 30, 2004; 101(13): 4572 - 4577. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Aandahl, J. Michaelsson, W. J. Moretto, F. M. Hecht, and D. F. Nixon Human CD4+ CD25+ Regulatory T Cells Control T-Cell Responses to Human Immunodeficiency Virus and Cytomegalovirus Antigens J. Virol., March 1, 2004; 78(5): 2454 - 2459. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Zheng, J. H. Wang, M. N. Koss, F. Quismorio Jr., J. D. Gray, and D. A. Horwitz CD4+ and CD8+ Regulatory T Cells Generated Ex Vivo with IL-2 and TGF-{beta} Suppress a Stimulatory Graft-versus-Host Disease with a Lupus-Like Syndrome J. Immunol., February 1, 2004; 172(3): 1531 - 1539. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Chen, W. Jin, N. Hardegen, K.-j. Lei, L. Li, N. Marinos, G. McGrady, and S. M. Wahl Conversion of Peripheral CD4+CD25- Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-{beta} Induction of Transcription Factor Foxp3 J. Exp. Med., December 15, 2003; 198(12): 1875 - 1886. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. P. M. Koenen, E. Fasse, and I. Joosten IL-15 and Cognate Antigen Successfully Expand De Novo-Induced Human Antigen-Specific Regulatory CD4+ T Cells That Require Antigen-Specific Activation for Suppression J. Immunol., December 15, 2003; 171(12): 6431 - 6441. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Malek The main function of IL-2 is to promote the development of T regulatory cells J. Leukoc. Biol., December 1, 2003; 74(6): 961 - 965. [Abstract] [Full Text] |
||||
![]() |
L. Cosmi, F. Liotta, E. Lazzeri, M. Francalanci, R. Angeli, B. Mazzinghi, V. Santarlasci, R. Manetti, V. Vanini, P. Romagnani, et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes Blood, December 1, 2003; 102(12): 4107 - 4114. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Doyen, M. Rubio, D. Braun, T. Nakajima, J. Abe, H. Saito, G. Delespesse, and M. Sarfati Thrombospondin 1 Is an Autocrine Negative Regulator of Human Dendritic Cell Activation J. Exp. Med., October 20, 2003; 198(8): 1277 - 1283. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Vigouroux, E. Yvon, H.-J. Wagner, E. Biagi, G. Dotti, U. Sili, C. Lira, C. M. Rooney, and M. K. Brenner Induction of Antigen-Specific Regulatory T Cells following Overexpression of a Notch Ligand by Human B Lymphocytes J. Virol., October 15, 2003; 77(20): 10872 - 10880. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Horwitz, S. G. Zheng, and J. D. Gray The role of the combination of IL-2 and TGF-{beta} or IL-10 in the generation and function of CD4+ CD25+ and CD8+regulatory T cell subsets J. Leukoc. Biol., October 1, 2003; 74(4): 471 - 478. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Mizobuchi, K. Yasufuku, Y. Zheng, M. A. Haque, K. M. Heidler, K. Woods, G. N. Smith Jr., O. W. Cummings, T. Fujisawa, J. S. Blum, et al. Differential Expression of Smad7 Transcripts Identifies the CD4+CD45RChigh Regulatory T Cells That Mediate Type V Collagen-Induced Tolerance to Lung Allografts J. Immunol., August 1, 2003; 171(3): 1140 - 1147. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-m. Chen, M. J. O'Shaughnessy, I. Gramaglia, A. Panoskaltsis-Mortari, W. J. Murphy, S. Narula, M. G. Roncarolo, and B. R. Blazar IL-10 and TGF-{beta} induce alloreactive CD4+CD25- T cells to acquire regulatory cell function Blood, June 15, 2003; 101(12): 5076 - 5083. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Game, M. P. Hernandez-Fuentes, A. N. Chaudhry, and R. I. Lechler CD4+CD25+ Regulatory T Cells Do Not Significantly Contribute to Direct Pathway Hyporesponsiveness in Stable Renal Transplant Patients J. Am. Soc. Nephrol., June 1, 2003; 14(6): 1652 - 1661. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Yin, N. Dujovny, L. Ma, A. Varghese, J. Shen, D. K. Bishop, and A. S. Chong IFN-{gamma} Production Is Specifically Regulated by IL-10 in Mice Made Tolerant with Anti-CD40 Ligand Antibody and Intact Active Bone J. Immunol., January 15, 2003; 170(2): 853 - 860. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Zheng, J. D. Gray, K. Ohtsuka, S. Yamagiwa, and D. A. Horwitz Generation Ex Vivo of TGF-{beta}-Producing Regulatory T Cells from CD4+CD25- Precursors J. Immunol., October 15, 2002; 169(8): 4183 - 4189. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lehmann, J. Huehn, M. de la Rosa, F. Maszyna, U. Kretschmer, V. Krenn, M. Brunner, A. Scheffold, and A. Hamann Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells PNAS, October 1, 2002; 99(20): 13031 - 13036. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Rutella, L. Pierelli, G. Bonanno, S. Sica, F. Ameglio, E. Capoluongo, A. Mariotti, G. Scambia, G. d'Onofrio, and G. Leone Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells Blood, September 18, 2002; 100(7): 2562 - 2571. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Somasundaram, L. Jacob, R. Swoboda, L. Caputo, H. Song, S. Basak, D. Monos, D. Peritt, F. Marincola, D. Cai, et al. Inhibition of Cytolytic T Lymphocyte Proliferation by Autologous CD4+/CD25+ Regulatory T Cells in a Colorectal Carcinoma Patient Is Mediated by Transforming Growth Factor-{beta} Cancer Res., September 15, 2002; 62(18): 5267 - 5272. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Annunziato, L. Cosmi, F. Liotta, E. Lazzeri, R. Manetti, V. Vanini, P. Romagnani, E. Maggi, and S. Romagnani Phenotype, Localization, and Mechanism of Suppression of CD4+CD25+ Human Thymocytes J. Exp. Med., August 5, 2002; 196(3): 379 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Piccirillo, J. J. Letterio, A. M. Thornton, R. S. McHugh, M. Mamura, H. Mizuhara, and E. M. Shevach CD4+CD25+ Regulatory T Cells Can Mediate Suppressor Function in the Absence of Transforming Growth Factor {beta}1 Production and Responsiveness J. Exp. Med., July 15, 2002; 196(2): 237 - 246. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Dieckmann, C. H. Bruett, H. Ploettner, M. B. Lutz, and G. Schuler Human CD4+CD25+ Regulatory, Contact-dependent T Cells Induce Interleukin 10-producing, Contact-independent Type 1-like Regulatory T Cells J. Exp. Med., July 15, 2002; 196(2): 247 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Chiffoleau, G. Beriou, P. Dutartre, C. Usal, J.-P. Soulillou, and M. C. Cuturi Role for Thymic and Splenic Regulatory CD4+ T Cells Induced by Donor Dendritic Cells in Allograft Tolerance by LF15-0195 Treatment J. Immunol., May 15, 2002; 168(10): 5058 - 5069. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Taylor, C. J. Lees, and B. R. Blazar The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host disease lethality Blood, May 15, 2002; 99(10): 3493 - 3499. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Y. Woo, H. Yeh, C. S. Chu, K. Schlienger, R. G. Carroll, J. L. Riley, L. R. Kaiser, and C. H. June Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation J. Immunol., May 1, 2002; 168(9): 4272 - 4276. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |